Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.

Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable ...